Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: A randomized controlled trial

Annals of Surgical Oncology

Volumn 17, Issue 12, 2010, Pages 3137-3144

  Xia, Yong ^a   Qiu, Yinghe ^a   Li, Jun ^a   Shi, Lehua ^a   Wang, Kui ^a   Xi, Tao ^a   Shen, Feng ^a   Yan, Zhenlin ^a   Wu, Mengchao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BATILOL; CAPECITABINE; HEMATOLOGIC AGENT; LEUCOGENENOL; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; DERMATITIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG FEVER; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FOLLOW UP; HAIR LOSS; HUMAN; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; POSTOPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE CARE; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650984411     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1148-3     Document Type: Article

References (42)

1. DM Parkin F Bray J Ferlay P Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin. 55 74 108 10.3322/canjclin.55.2.74 15761078
2. SZ Yu 1995 Primary prevention of hepatocellular carcinoma J Gastroenterol Hepatol. 10 674 682 1:STN:280:DyaK287mtl2gsg%3D%3D 10.1111/j.1440-1746.1995. tb01370.x 8580413
3. CH Chang GY Chau WY Lui SH Tsay KL King CW Wu 2004 Long-term results of hepatic resection for hepatocellular carcinoma originating from the noncirrhotic liver Arch Surg. 139 320 325 10.1001/archsurg.139.3.320 15006892 discussion 326 (Pubitemid 38282676)
4. PR Tung-Ping ST Fan J Wong 2000 Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma Ann Surg. 232 10 24 10.1097/00000658-200007000-00003 (Pubitemid 30456545)
5. EC Lai CM Lo ST Fan CL Liu J Wong 1998 Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial Arch Surg. 133 183 188 1:STN:280:DyaK1c7ktlalsw%3D%3D 10.1001/archsurg.133.2.183 9484732 (Pubitemid 28092919)
6. K Takenaka K Yoshida T Nishizaki D Korenaga K Hiroshige T Ikeda, et al. 1995 Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma Am J Surg. 169 400 404 1:STN:280:DyaK2M3gvV2qtg%3D%3D 10.1016/S0002-9610(99)80184-6 7694977 discussion 405
7. CM Lo CL Liu SC Chan CM Lam RT Poon IO Ng, et al. 2007 A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma Ann Surg. 245 831 842 10.1097/01.sla.0000245829.00977. 45 17522506 (Pubitemid 46809282)
8. T Takayama T Sekine M Makuuchi S Yamasaki T Kosuge J Yamamoto, et al. 2000 Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial Lancet. 356 802 807 1:STN:280:DC%2BD3cvmvVSltg%3D%3D 10.1016/S0140-6736(00)02654-4 11022927
9. Y Muto H Moriwaki M Ninomiya S Adachi A Saito KT Takasaki, et al. 1996 Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group N Engl J Med. 334 1561 1567 1:CAS:528:DyaK28XksVCgsLk%3D 10.1056/NEJM199606133342402 8628336 (Pubitemid 26177483)
10. T Ono A Yamanoi EAO Nazmy H Kohno N Nagasue 2001 Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials Cancer. 91 2378 2385 1:CAS:528:DC%2BD3MXltVOnsLc%3D 10.1002/1097- 0142(20010615)91:12<2378::AID-CNCR1271>3.0.CO;2-2 11413528 (Pubitemid 32552825)
11. M Yamamoto S Arii K Sugahara T Tobe 1996 Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma Br J Surg. 83 336 340 1:STN:280:DyaK283ks1amtw%3D%3D 10.1002/bjs.1800830313 8665186 (Pubitemid 26083165)
12. H Kohno N Nagasue T Hayashi A Yamanoi M Uchida T Ono, et al. 1996 Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC) Hepatogastroenterology. 43 1405 1409 1:CAS:528:DyaK2sXit1WntA%3D%3D 8975939
13. T Ono N Nagasue H Kohno T Hayashi M Uchida H Yukaya, et al. 1997 Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study Semin Oncol. 24 S6-25 S6-18
14. K Hasegawa T Takayama M Ijichi Y Matsuyama H Imamura K Sano, et al. 2006 Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial Hepatology. 44 891 895 1:CAS:528:DC%2BD28XhtFyqsrzP 10.1002/hep.21341 17006925 (Pubitemid 46489553)
15. J Schuller J Cassidy E Dumont B Roos S Durston L Banken, et al. 2000 Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Cancer Chemother Pharmacol. 45 291 297 1:CAS:528:DC%2BD3cXhtlCrtLk%3D 10.1007/s002800050043 10755317
16. T Ishikawa M Utoh N Sawada M Nishida Y Fukase F Sekiguchi, et al. 1998 Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts Biochem Pharmacol. 55 1091 1097 1:CAS:528:DyaK1cXitlSiurk%3D 10.1016/S0006-2952(97)00682-5 9605432 (Pubitemid 28167730)
17. J Zhou ZY Tang J Fan ZQ Wu Y Ji YS Xiao, et al. 2003 Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor Clin Cancer Res. 9 6030 6037 1:CAS:528:DC%2BD3sXpsl2lsLg%3D 14676129
18. J Zhou ZY Tang ZQ Wu, et al. 2001 Capecitabine inhibition of recurrence and metastasis after liver cancer resection in nude mice Chin J Surg. 39 199 201
19. J Zhou ZY Tang J Fan, et al. 2000 Study on inhibition of the growth and metastasis of LCID20 hepatocellular carcinoma by capecitabine Chin J Exp Surg. 17 403 405
20. ST Fan CM Lo CL Liu CM Lam WK Yuen C Yeung, et al. 1999 Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths Ann Surg. 229 322 330 1:STN:280:DyaK1M7nsVKlsw%3D%3D 10.1097/00000658-199903000-00004 10077043
21. JM Llovet AM Di Bisceglie J Bruix BS Kramer R Lencioni AX Zhu, et al. 2008 Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst. 100 698 711 10.1093/jnci/djn134 18477802
22. WY Lau TW Leung SK Ho M Chan D Machin J Lau, et al. 1999 Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial Lancet. 353 797 801 1:CAS:528:DyaK1MXhvFemsbc%3D 10.1016/S0140-6736(98)06475-7 10459961 (Pubitemid 29110405)
23. WY Lau EC Lai TW Leung SC Yu 2008 Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival Ann Surg. 247 43 48 10.1097/SLA.0b013e3181571047 18156922
24. E Boucher G Bouguen E Garin A Guillygomarch K Boudjema JL Raoul 2008 Adjuvant intraarterial injection of 131I-labeled lipiodol after resection of hepatocellular carcinoma: progress report of a case-control study with a 5-year minimal follow-up J Nucl Med. 49 362 366 10.2967/jnumed.107.044750 18287267 (Pubitemid 351355200)
25. HC Sun ZY Tang L Wang LX Qin ZC Ma QH Ye, et al. 2006 Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial J Cancer Res Clin Oncol. 132 458 465 1:CAS:528:DC%2BD28Xks1emtbo%3D 10.1007/s00432-006-0091-y 16557381
26. D Hui L Qiang W Jian Z Ti K Da-Lu 2009 A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma Dig Liver Dis. 41 36 41 10.1016/j.dld.2008.04.007 18818130
27. JD Schwartz M Schwartz J Mandeli M Sung 2002 Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials Lancet Oncol. 3 593 603 10.1016/S1470-2045(02)00873-2 12372721 (Pubitemid 35174678)
28. Samuel M, Chow PK, Chan SE, Machin D, Soo KC. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev. 2009;CD001199.
29. YS Xiao ZY Tang J Fan J Zhou ZQ Wu QM Sun, et al. 2004 Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice J Cancer Res Clin Oncol. 130 546 550 1:CAS:528:DC%2BD2cXmt1Krtb4%3D 10.1007/s00432-004-0565-8 15071737
30. JH Shim JW Park BH Nam WJ Lee CM Kim 2009 Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma Cancer Chemother Pharmacol. 63 459 467 1:CAS:528:DC%2BD1cXhsFejtrvP 10.1007/s00280-008-0759-x 18437384
31. DS von C Lersch M Mayr K Stock E Schulte-Frohlinde RM Schmid, et al. 2007 Capecitabine for treatment of advanced hepatocellular carcinoma Hepatogastroenterology. 54 2310 2314
32. YZ Patt MM Hassan A Aguayo AK Nooka RD Lozano SA Curley, et al. 2004 Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma Cancer. 101 578 586 1:CAS:528:DC%2BD2cXmslChs74%3D 10.1002/cncr.20368 15274071 (Pubitemid 38970609)
33. V Boige JL Raoul JP Pignon O Bouche JF Blanc L Dahan, et al. 2007 Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial Br J Cancer. 97 862 867 1:CAS:528:DC%2BD2sXhtFSnurfN 17876335 (Pubitemid 47519302)
34. RT Poon 2009 Differentiating early and late recurrences after resection of HCC in cirrhotic patients: implications on surveillance, prevention, and treatment strategies Ann Surg Oncol. 16 792 794 10.1245/s10434-009-0330-y 19190964
35. JM Llovet J Bruix 2008 Novel advancements in the management of hepatocellular carcinoma in 2008 J Hepatol. 48 S20 S37 1:CAS:528: DC%2BD1cXjtlelsL0%3D 10.1016/j.jhep.2008.01.022 18304676
36. N Portolani A Coniglio S Ghidoni M Giovanelli A Benetti GA Tiberio, et al. 2006 Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications Ann Surg. 243 229 235 10.1097/01.sla.0000197706.21803.a1 16432356 (Pubitemid 43185442)
37. GY Chau WY Lui CW Chi YP Chau AF Li HL Kao, et al. 2008 Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection Eur J Surg Oncol. 34 333 338 17218078
38. RH Hu PH Lee SC Yu JC Sheu MY Lai 1999 Serum hepatocyte growth factor before and after resection for hepatocellular carcinoma Hepatogastroenterology. 46 1842 1847 1:STN:280:DyaK1MzlslChtA%3D%3D 10430357
39. KP de Jong 2004 Hepatocyte growth factor serum levels after partial hepatectomy Transplantation. 78 1089 10.1097/01.TP.0000132787.40732.42 15480182 author reply 1089-90 (Pubitemid 39391877)
40. N Horiguchi H Takayama M Toyoda T Otsuka T Fukusato G Merlino, et al. 2002 Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine Oncogene. 21 1791 1799 1:CAS:528:DC%2BD38Xis1ahtb8%3D 10.1038/sj.onc.1205248 11896611
41. MK Whitworth A Sheen DD Rosa SE Duff D Ryder A Burumdayal, et al. 2006 Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factor J Cancer Res Clin Oncol. 132 41 44 1:CAS:528:DC%2BD2MXht1Gnu7jF 10.1007/s00432-005-0037-9 16249905 (Pubitemid 41712805)
42. SH Park Y Lee SH Han SY Kwon OS Kwon SS Kim, et al. 2006 Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma BMC Cancer. 6 3 10.1186/1471-2407-6-3 16396674 (Pubitemid 43078827)